Weekly briefings on funding, launches, leadership moves and hiring signals across life sciences and industrial markets, written by the QP Group specialists who work in them every day.
Funding, launches, leadership moves and hiring signals across the companies building the future of science and healthcare.
Infrastructure funding, contractor consolidation, project awards and leadership moves across US construction and manufacturing.
The stories that mattered last week, across every market we cover.
The Barcelona start-up behind the HER2DX breast cancer test joins Hologic's oncology diagnostics, alongside its Breast Cancer Index. Price not disclosed.
Read the full story →Fresh off selling Vega to Incyte and floating Electra, the team is restarting with a preclinical hematology and immunology pipeline. Janus Henderson says it rarely invests this early.
Read the full story →Reuters reports BASF has lifted its offer to €24 a share, about €11.18bn, and is pledging no compulsory redundancies until 2032.
Read the full story →$1.275bn upfront for Phase 1 HCXT-2001, days after its own oral IBD drug emvistegrast hit in Phase 2. An all-oral IBD combination is the plan.
Read the full story →Q3 revenue hit $3.77bn and backlog reached $17.81bn. Management says labour, not demand, is what limits growth.
Read the full story →FHWA disaster money goes to 34 states plus DC and four territories. North Carolina gets $873M for Hurricane Helene repairs.
Read the full story →Q3 sales held at $235.9M and utility water was flat, but gross margin rose to 41.9%. Management expects revenue to improve into 2027 as awarded utility projects ramp.
Read the full story →Signing as self-funded employers, they're asking their insurers and TPAs to extend the pledge's electronic prior auth improvements to their own health plans.
Read the full story →Supplemental SRF funding ended on 30 Sept, and contractors are pushing Congress to reauthorise at IIJA levels. Without that, federal water funding could fall by about 60% in FY27.
Read the full story →27 companies cut 2,568 people, about 90% fewer than a year ago and the lowest quarter since BioSpace started tracking. New Jersey was hit hardest.
Read the source →Agents now run whole R&D workflows, with scientists approving key steps. Benchling calls agents its fastest-growing product.
Read the full story →Long reads will join its rare disease genome testing to catch structural variants and repeat expansions that short reads can miss. Early access is due by year-end.
Read the full story →Read any newsletter in full.
27 Oct 2026 · Genomics & Diagnostics
27 Oct 2026 · Biotech, R&D & Clinical
27 Oct 2026 · Materials Science & Cheminformatics
27 Oct 2026 · Therapeutics
27 Oct 2026 · MEP
27 Oct 2026 · Heavy Civil & Infrastructure
Pick the markets you care about. Each is a three-minute weekly read, written by the QP Group specialist for that market. No spam, one-click unsubscribe.
